Preimplantation genetic testing is considered in a similar approach to prenatal diagnosis. It is used to screen for a specific genetic disease and avoids selective abortion. Preimplantation genetic testing is a technique used for an early form of prenatal genetic diagnosis where abnormal embryos are identified, and only genetically normal embryos are used for implantation. It is used to identify genetic defects in embryos created through in vitro fertilization before pregnancy. Preimplantation genetic screening refers to techniques where embryos from presumed chromosomally normal genetic parents are screened for aneuploidy. PGT is highly adopted to prevent the risk of heritable genetic diseases in a child before implantation, thereby eliminating the dilemma of pregnancy termination following unfavorable prenatal diagnosis.
The global preimplantation genetic testing market size is valued at USD 434.4million in 2019 and is projected to reach USD 775.1 million by 2027, growing at a CAGR of 8.6% during the forecast period 2020-2027. The major aid in the growing demand for preimplantation genetic testing is the rising fertility rate and the rising demand for early detection of chromosomal abnormalities in an embryo. Additionally, the increasing incidence of a single gene, mitochondrial, and other gene-related disorders will spur the future periods’ global preimplantation genetic testing industry. Furthermore, the growing public-private funding for preimplantation genetic testing and an increasing number of fertility clinics is expected to witness remarkable growth of preimplantation genetic testing. The increased risk of chromosomal abnormalities in the fetus due to increasing maternal age is expected to propel the demand for preimplantation genetic testing over the coming years.
Moreover, the number of supportive government initiatives to support reproductive health positively impacts the market for the preimplantation genetic testing industry. Furthermore, the rapid expansion in customer base, rise in the extensive R&D activities at the academic and industrial level, and increasing technological advancements in genetic analysis fuel the demand for the preimplantation genetic testing market. Additionally, the growing geriatric disorders and increasing healthcare demands in the developing world propelling the growth of the preimplantation genetic testing market across the globe.
Preimplantation genetic testing involves testing embryos to detect abnormal chromosomes before they are transferred to the uterus. Moreover, the ongoing trend of replacing traditional genomic technologies with advanced genetic technologies such as FISH and NGS. Due to the supremacy of large market size, low market concentration, and ripe technology applications, genetic testing technology has attracted various enterprises to the layout. However, awareness regarding health of fetus among couples and high procedures cost associated with preimplantation genetic testing are the key factors restraining the growth of the market.
The global preimplantation genetic testing market is segregated into reagents & consumables, instruments, and software & services based on the product and service.
The reagents & consumables segment is estimated to witness the highest growth over the analysis timeframe due to increasing kits in IVF laboratories, rising prevalence of genetic disorders, and increasing research to improve human reproduction.
The instruments will grow significantly due to the rising adoption of preimplantation genetic testing systems and the rise in the utilization of preimplantation genetic screening technology.
Based on the technology, the global preimplantation genetic testing market is categorized into next-generation sequencing, polymerase chain reaction, fluorescent in-situ hybridization, comparative genomic hybridization, and single nucleotide polymorphism.
The next-generation sequencing segment held for a significant market share in 2019 and will gain maximum market revenue by 2027. It is attributable to the widespread advantages such as better ability to detect an embryo with differing results, reduction in cost & human errors due to increased automation, and enhanced detection of structural abnormalities such as chromosomes.
The fluorescent in-situ hybridization segment is poised to witness significant growth over the forecast period. It offers high sensitivity & specificity in recognizing targeted DNA or RNA sequences and rapid turnover with high efficiency of hybridization and detection. In addition, FISH is highly adopted in monitoring the success of bone marrow transplantation.
The global preimplantation genetic testing market is listed into preimplantation genetic screening and preimplantation genetic diagnosis based on the procedure type.
The preimplantation genetic screening segment held a significant market share in 2019 and will gain maximum market revenue by 2027. It is attributable to the advantages such as reduced risks of miscarriage & IVF cycle time, better implantation rate, and increased chances of healthy pregnancy across all age groups.
The preimplantation genetic diagnosis segment is poised to witness significant growth over the forecast period due to growing awareness towards genetic testing of a specific gene mutation and the rising prevalence of single-gene diseases.
Based on the application, the global preimplantation genetic testing market is classified into aneuploidy, structural chromosomal abnormalities, single-gene disorders, x-linked disorders, HLA typing, and gender identification.
The aneuploidy is expected to be the highest revenue share for preimplantation genetic testing during the forecast period. The segment’s extension is primarily attributed to the increasing maternal age and increasing incidence of aneuploidy.
The HLA typing will witness a lucrative growth rate in the estimated period due to a higher survival rate in hematopoietic stem cell transplantation from interconnected matched donors, provides more successful renal transplantation, platelet transfusion, paternity testing, and even serving as a diagnostic test for ankylosing spondylitis.
Based on the end-user, the global preimplantation genetic testing market is segmented into maternity centers & fertility clinics, hospitals, diagnostic labs & service providers, and research laboratories & academic institutes.
The maternity centers &fertility clinics segment will dominate the global preimplantation genetic testing market by 2027 due to the high treatment success rate at these centers, the surge in fertility clinics, and rising demand for infertility treatments.
The hospitals, diagnostic labs, and service providers accounted for the largest share of the preimplantation genetic testing market in 2019. The increasing use of preimplantation genetic testing technology in hospitals, economic expansion, and government focus broader healthcare policies.
By geography, the global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America is estimated to project considerable ballooning over 2020-2026. It is owing to advents in technology, the rising number of IVF procedures, and increasing healthcare expenditure.
The Asia Pacific will capture a well-known share of the preimplantation genetic testing market by 2027. Due to leading industry players offering innovative products, continually improving healthcare infrastructure in the region, and mounting health care expenditures in emerging countries such as India and China.
Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, PerkinElmer Inc, Cooper Surgical Inc, Beijing Genomics Institute, Genea Limited, Oxford Gene Technology, and Rubicon Genomics Inc, the key players in the global preimplantation genetic testing market.
By Product & Services
By Procedure Type